Planned reductions in pharmaceutical investments linked to upcoming healthcare reforms are generating strong criticism. Politicians argue that companies should not dictate legislation through threats of withdrawal. The Green Party’s health policy spokesperson, Janosch Dahmen, criticized the practice, stating that laws must be made in parliament rather than by the executive boards of international pharma giants. He warned against allowing industry pressure to intimidate policymakers, emphasizing that businesses are not meant to use social contribution funds to safeguard the profit margins of private pharmaceutical companies. According to Dahmen, if multi-billion euro corporations link their investments to guaranteed public funding from social cash registers, they are undermining the competitiveness of Germany’s economy.
This pushback stems primarily from a planned law aimed at stabilizing the basic health insurance (GKV) contribution rates. Major drug manufacturers like Eli Lilly and Boehringer Ingelheim have reportedly threatened significant cuts to their German investments, either directly or indirectly referencing Health Minister Nina Warken’s proposal. The core point of contention is a “dynamic manufacturer discount” designed to provide a price reduction to sickness funds, with the size of this discount being determined by the mandatory revenues and drug expenditures of those public insurers.
The criticism from the Left Party has been sharp, with Michael Arndt characterizing these investment withdrawal announcements as an “outright attempt at extortion based purely on greed.” He argued that these corporations are demanding that German health insurance participants generate even greater profits for their shareholders.
Even within parties governing the current administration, skepticism is evident. Simone Borchardt of the CDU Union faction expressed reservations about creating healthcare policy under duress, noting that policymakers bear responsibility toward those who pay contributions. While acknowledging that Germany has high drug expenditures in many areas, she stressed that every interference risks impacting either supply or local economic standing.
Despite her caution, Borchardt maintained that the planned legislation is necessary to achieve stability in contribution rates, suggesting that all sectors must contribute equally. However, she also announced her intention to “carefully examine” the legislative draft within the parliamentary process, even looking into potential unintended negative consequences related to research, production, or medicine availability.
